Comparative Pharmacology

Head-to-head clinical analysis: JANUMET XR versus SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE.

Peer-Reviewed Evidence

Differential Analysis

JANUMET XR vs SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

JANUMET XR

DPP-4 Inhibitor/Biguanide Combination

Category C

SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE

DPP-4 Inhibitor

Category A/B

Head-to-Head

Clinical Matrix

Mechanism of Action

JANUMET XR is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases active incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.

Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), increasing endogenous incretin hormones (GLP-1, GIP) which enhance insulin secretion and decrease glucagon levels in a glucose-dependent manner. Metformin activates AMP-activated protein kinase (AMPK), decreasing hepatic glucose production and improving insulin sensitivity.

Clinical Dosing

One tablet orally once daily, with evening meal; initial dose based on patient's current sitagliptin and metformin doses, or new patients: starting dose 50 mg sitagliptin/500 mg metformin XR; maximum dose 100 mg sitagliptin/2000 mg metformin XR per day.

Initial dose based on current metformin dose: for patients not on metformin, start with sitagliptin 50 mg/metformin 500 mg PO BID; for metformin monotherapy, switch to sitagliptin 50 mg/metformin 500 mg or 1000 mg PO BID; for patients on sitagliptin, start with sitagliptin 50 mg/metformin 500 mg or 1000 mg PO BID. Maximum daily dose: sitagliptin 100 mg, metformin 2000 mg.

Direct Interaction